3.4.2.3. drug treatment. single, optimal, medical therapy neuro-urological symptoms always available. commonly, combination different therapies (e.g. intermittent catheterisation antimuscarinic drugs) advised prevent urinary tract damage improve long-term outcomes, particularly patients suprasacral sci ms [145,178-180]. drug treatments categorised depending mechanism action focus storage voiding symptoms. 3.4.2.3.1. drugs storage symptoms antimuscarinic drugs: first-line choice treating ndo, increasing bladder capacity reducing episodes ui secondary ndo inhibition parasympathetic pathways [134,181-187]. antimuscarinic drugs used many years treat patients ndo , responses individual patients antimuscarinic treatment variable. despite meta-analysis confirming clinical urodynamic efficacy antimuscarinic therapy compared placebo adult ndo, recent integrative review indicated information provided still limited clinicians able match trial data needs individual patients sci, mainly due lack use standardised clinical evaluation tools american spinal injury association bladder diary validated symptoms score . higher doses combination antimuscarinic agents may option maximise outcomes neurological patients [182,183,190-193]. however, drugs high incidence adverse events, may lead early discontinuation therapy. despite this, ndo patients generally shown better treatment adherence compared idiopathic patients . choice antimuscarinic agent: oxybutynin , trospium , tolterodine propiverine established, effective well-tolerated treatments even long-term use . darifenacin solifenacin evaluated ndo secondary sci ms [186,201-203] results similar antimuscarinic drugs. pilot study using solifenacin ndo due pd showed improvement ui . fesoterodine, active metabolite tolterodine, also introduced; improving urodynamic variables sci, ms pd patients . fesoterodine sci patients diminish magnitude frequency ad episodes . favourable results new drug imidafenacin reported suprapontine well sci patients . side effects: controlled-release antimuscarinics minor side effects, e.g. dry mouth . suggested different ways administration may help reduce side effects . imidafenacine safely used neurological patients worsening cognitive function . nevertheless, potential risk developing dementia taken account ; consider switching beta-3 agonists therapies cognition affected . beta-3-adrenergic receptor agonists despite increasing use mirabegron neuro urological patients, role patients still unclear . ms sci patients, short follow-up, mirabegron demonstrated significant effect detrusor pressure cystometric capacity , despite reported improvement lut symptoms quality life similar antimuscarinics . cardiovascular safety ndo population suggested placebo-controlled rct . significant subjective improvement ndo symptoms also reported using lower dosages mirabegron patients affected cns lesions without negative effects voiding function . standard dosage 50 mg found effective worsening cognitive function patients pd . vibegron treatments significantly improved maximum cystometric capacity, bladder compliance, ndo retrospective cohort study , studies needed recommendation. drugs sr found desmopressin may effective treating nocturnal polyuria ms patients; however, adverse events common, included studies heterogeneous low quality . combination therapy mirabegron desmopressin ms patients shown promising results; however, clinical experience still limited neuro-urological populations . preliminary studies, improvements daily incontinence rates, nocturia, daytime 24-hour voids, well low risk adverse events, suggest cannabinoids may effective safe ms patients . concomitant improvement ndo symptoms reported male ms patients using daily tadalafil treat neurogenic erectile dysfunction (ed) . 3.4.2.3.2. drugs voiding symptoms detrusor underactivity: cholinergic drugs, bethanechol distigmine, considered enhance detrusor contractility promote bladder emptying, frequently used clinical practice . preclinical studies documented potential benefits cannabinoid agonists improving detrusor contractility administered intravesically . decreasing bladder outlet resistance: Î±-blockers (e.g. tamsulosin, naftopidil silodosin) seem effective decreasing bladder outlet resistance, pvr ad [231-235]. increasing bladder outlet resistance: several drugs shown efficacy selected cases mild sui, high-level evidence studies neurological patients .